Altered signature of apoptotic endothelial cell-derived microvesicles predicts chronic heart failure phenotypes

• Published in: Biomarkers in medicine Vol. 13; no. 9; pp. 737 - 750
• Main Authors: Berezin, Alexander E, Kremzer, Alexander A, Samura, Tatyana A, Berezina, Tatyana A
• Format: Journal Article
• Language: English
• Published: England Future Medicine Ltd 01.06.2019
• Subjects: Annexin A5 - blood; Annexin V; Antigens, CD - blood; Apoptosis; Biomarkers; Biomarkers - blood; Cadherins - blood; Cardiovascular disease; Cell-Derived Microparticles - metabolism; Cell-Derived Microparticles - pathology; chronic heart failure; Clinical outcomes; Cohort Studies; Collaboration; Congestive heart failure; Diabetes; endothelial cell-derived microvesicles; Endothelial cells; Endothelial Cells - pathology; Endothelium; Extracellular Vesicles - pathology; Female; Galectin 3 - blood; galectin-3; Heart attacks; Heart failure; Heart Failure - blood; Heart Failure - physiopathology; Hospitals; Humans; Hypertension; Inflammation; Interleukin-1 Receptor-Like 1 Protein - blood; Kidney diseases; Male; Middle Aged; Natriuretic Peptide, Brain - blood; natriuretic peptides; Peptide Fragments - blood; Peptides; Phenotype; Phenotypes; Platelet Endothelial Cell Adhesion Molecule-1 - blood; Prospective Studies; soluble suppressor of tumorogenicity-2; Stroke Volume; Studies; Ultrasonic imaging; Ventricle; Ventricular Remodeling; United States > US; Germany; natriuretic peptides; endothelial cell-derived microvesicles; chronic heart failure; soluble suppressor of tumorogenicity-2; galectin-3; biomarkers
• ISSN: 1752-0363; 1752-0371
• DOI: 10.2217/bmm-2018-0449

: to evaluate the associations between signatures of apoptotic endothelial cell-derived microvesicles (MVs) with phenotypes of chronic heart failure (HF). The study cohort consisted of 388 prospectively involved subjects with HF patients with predominantly reduced left ventricular ejection fraction (HFrEF), HF with preserved ejection fraction (HFpEF) and HF with mid-range ejection fraction (HFmrEF). All biomarkers were measured at baseline. The number of circulating CD31 /annexin V MVs in HFrEF and HFmrEF patients was similar. The number of circulating CD144 /annexin V MVs in HFrEF patients was significantly higher than HFmrEF and HFpEF. We determined that a combination of number of circulating CD31 /annexin V MVs and Gal-3 was the best predictor of HFpEF and that number of circulating CD144 /annexin V MVs is able to increase predictive capabilities of soluble ST2 (sST2) and Gal-3 for HFrEF. We found that the number of circulating CD31 /annexin V MVs may improve a predictive capacity for conventional HF biomarkers.